While bortezomib exerts its major activity by inhibiting the chymotrypsin-like proteolytic activity of the 26S proteasome and promoting the accumulation of inefficiently degraded proteins leading to apoptosis, several studies have also shown that it is a key player in sensitization of MM cells to apoptosis induced by TRAIL/APO2L via upregulation of TRAIL receptors 1 and 2[4]. Here, TNFSF10 is linked to Miyoshi myopathy.